The modern longevity race is no longer organized around a single theory of aging. Three experimental programs—ER-100, RTR242 and RLS-1496—illustrate how differently biotechnology companies are trying to intervene in biological decline. One attempts to reset gene-expression patterns in damaged retinal cells. Another aims to restart cellular recycling. The third targets pathological senescent cells in diseased skin.
Together, they represent a meaningful transition from laboratory geroscience toward human testing. They do not, however, show that medicine can already slow or reverse whole-body human aging. Each candidate remains investigational, each is being developed first for a defined disease, and the most important clinical questions are still unanswered.
ER-100: reprogramming without erasing identity
Life Biosciences’ ER-100 is the most conceptually ambitious of the three. The eye-directed gene therapy uses modified adeno-associated viral vectors to deliver instructions for three transcription factors—OCT4, SOX2 and KLF4, collectively called OSK. These factors are intended to partially restore youthful epigenetic patterns without pushing mature cells all the way back into a stem-cell state.
The FDA cleared the program for a Phase 1 study in people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy. ER-100 is injected into one eye, while oral doxycycline controls OSK expression for eight weeks. The trial is primarily designed to evaluate safety, tolerability and immune responses, although investigators will also monitor vision. A five-year follow-up reflects the caution required for an experimental gene therapy.
RTR242: repairing the cellular recycling system
Retro Biosciences’ RTR242 takes a small-molecule approach. The oral candidate is designed to improve lysosomal function and autophagic flux—the linked systems cells use to break down and recycle damaged proteins and other components. Those processes become less efficient with age and are implicated in neurodegenerative disease.
RTR242 entered a randomized, double-blind, placebo-controlled Phase 1 study in healthy adults in Australia. The protocol uses single- and multiple-ascending-dose cohorts to examine safety, tolerability and pharmacokinetics. Retro lists Alzheimer’s disease as the program’s initial clinical focus, but this first study is not designed to prove that RTR242 improves memory, treats Alzheimer’s or extends life.
RLS-1496: a more selective attack on senescent cells
Rubedo Life Sciences’ RLS-1496 is a topical GPX4-modulating senotherapeutic. It is intended to target pathological senescent and stressed cells while avoiding indiscriminate removal of every cell carrying a senescence marker. That distinction matters because senescence can contribute to chronic inflammation and tissue decline, but it also participates in wound healing and tumor suppression.
A registered open-label Phase 1b/2a study is testing 1 percent RLS-1496 cream on actinic keratoses, precancerous lesions associated with cumulative sun damage. Participants apply the cream to one forearm while the other remains untreated. Rubedo reported preliminary data from the first 18 evaluated participants showing a 46 percent reduction in lesion count at four weeks, compared with 11 percent on untreated arms. Those figures are company-reported preliminary results from a small, non-randomized study—not evidence of systemic rejuvenation.
The real milestone is testability
These candidates are compelling because they turn three influential aging mechanisms into clinical experiments. Their near-term value will be determined by narrower questions: Can controlled OSK expression be delivered safely to the eye? Can an oral molecule improve autophagy in humans at a tolerable dose? Can selective senotherapeutics change skin disease without unacceptable irritation or off-target effects?
Positive answers would not prove that aging has been reversed. They would establish something more useful: that specific mechanisms associated with aging can be manipulated safely enough to pursue meaningful disease outcomes. For longevity science, that is a more credible foundation than any promise of a universal age-reversal drug.
TENS Magazine conceptual illustration. This article describes investigational research and is not medical advice.
